News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

Connie Chen

Articles by Connie Chen

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

10 Real-World Effectiveness of Palbociclib (PAL) Plus Aromatase Inhibitors (AI) in Patients With Metastatic Breast Cancer (MBC) and Cardiovascular Diseases (CVD)

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Doris Makari,Rachel M. Layman,Hope S. Rugo, MD

August 20th 2024

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

28 Enhancing the Interpretation of Real-World Quality of Life (QoL) in Patients With Hormone Receptor– Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2-) Advanced Breast Cancer (ABC) Enrolled in the POLARIS Trial

ByGabrielle Rocque,Joanne L. Blum, MD, PhD,Yan Ji,Eric Gauthier,Yao Wang,Monica Z. Montelongo,Joseph C. Cappelleri,Connie Chen,Meghan S. Karuturi,Debu Tripathy, MD

July 24th 2024

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above

ByAdam M. Brufsky, MD, PhD,Xianchen Liu,Benjamin Li,Lynn McRoy,Connie Chen,Rachel M. Layman,Hope S. Rugo, MD

April 28th 2023

Latest Updated Articles

11 Real-world Treatment Patterns and Effectiveness of Palbociclib Plus an Aromatase Inhibitor in Patients With Metastatic Breast Cancer Aged 75 Years or Above
April 28th 2023

Trending on CancerNetwork

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

FDA Permits Expanded Daraxonrasib Access in Previously Treated Metastatic PDAC

Taletrectinib Demonstrates Durable Efficacy in ROS1-Positive NSCLC

Targeting KRAS in Pancreatic Cancer: What Is Daraxonrasib’s Mechanism of Action?

FDA ODAC Votes No to Camizestrant for HR+/HER2– ESR1 Advanced Breast Cancer